Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission by Nikos Viazis, Anastasios Karamanakos, Konstantinos Mousourakis, Angeliki Christidou, Fotios Fousekis, Konstantinos Mpakogiannis, Anastasios Koukoudis, Konstantinos Katsanos, Dimitrios Christodoulou, Myrto Cheila, Maria Tzouvala, Eirini Zacharopoulou, Maria Palatianou, Olga Giouleme, Olga Giouleme, Anastasia Katsoula, Anastasia Katsoula, Christos Liatsos, Nikolaos Kyriakos, Evi Zampeli, Evgenia Papathanasiou, Angeliki Theodoropoulou, Konstantinos Karmiris, Ioannis Psaroudakis, George Tribonias, Souzanna Gazi, Evangelia Mole, Theodoros Dimitroulas, Christos Koutsianas, Dimitris Vassilopoulos, George E. Fragoulis, Nikos Michalakeas, Charalampos Papagoras, Pantelis Panagakis, Marina Papoutsaki, Vasiliki Chasapi, Alexandros Stratigos, George Katsikas

Get full text